← Back to Search

Alkylating agents

panitumumab for Lung Cancer

Phase 2
Waitlist Available
Led By Martin J. Edelman, MD
Research Sponsored by Radiation Therapy Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up patients are followed until death. analysis occurs at time of primary analysis, approximately five years from start of study.
Awards & highlights

Study Summary

This trial is studying chemotherapy, radiation therapy, and panitumumab to treat patients with stage IIIA non-small cell lung cancer.

Eligible Conditions
  • Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~patients are followed until death. analysis occurs at time of primary analysis, approximately five years from start of study.
This trial's timeline: 3 weeks for screening, Varies for treatment, and patients are followed until death. analysis occurs at time of primary analysis, approximately five years from start of study. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab.
Secondary outcome measures
Ability of FDG-PET/CT Scan Data to Predict Outcome
Overall Survival
Patterns of First Failure
+3 more

Side effects data

From 2017 Phase 3 trial • 320 Patients • NCT00820248
94%
Dysphagia
92%
Acne
92%
Dry mouth
87%
Taste alteration
80%
Weight loss
77%
Fatigue
75%
Mucositis (clinical exam) Oral cavity
71%
Constipation
59%
Nausea
54%
Pain Throat/pharynx/larynx
50%
Dermatitis Chemoradiation
47%
Voice changes
45%
Dermatitis Radiation
43%
Anorexia
42%
Salivary gland changes
42%
Edema: head and neck
40%
Vomiting
37%
Dry skin
35%
Mucositis (functional/symptomatic) Oral cavity
33%
Mucositis (clinical exam) Pharynx
31%
Alopecia
30%
Heartburn
29%
Insomnia
28%
Pain Oral cavity
25%
Diarrhea
25%
Infection - Other
24%
Dehydration
24%
Cough
22%
Dermatology - Other
21%
Pain Head/headache
21%
Lymphopenia
21%
Hyperpigmentation
20%
Mood alteration Anxiety
20%
Edema, larynx
18%
Pain Middle ear
18%
Pain - Other
18%
Pain Neck
16%
Hand-foot
15%
Neuropathy-sensory
14%
Rigors/chills
14%
Hypothyroidism
14%
Trismus
14%
Hypertension
13%
Hearing (without monitoring program)
11%
Fibrosis-deep connective tissue
11%
Fever
11%
Pruritus
11%
Tinnitus
11%
Pain Tumor pain
10%
GI - Other
10%
Dyspnea
8%
Pain Abdomen NOS
8%
Mood alteration Depression
8%
Rash
7%
Muscle weakness Whole body/generalized
7%
Pain Back
7%
Hypopigmentation
6%
Infection with normal ANC Catheter-related
6%
Induration
6%
Telangiectasia
6%
Chelitis
6%
Pain Bone
6%
Pain Joint
6%
Sweating
6%
Dry eye
6%
Osteonecrosis
6%
Dizziness
5%
Pain External ear
5%
Neuropathy-motor
4%
Teeth
4%
Edema: limb
3%
Hearing (monitoring program)
3%
Hiccoughs
1%
Pain Extremity-limb
100%
80%
60%
40%
20%
0%
Study treatment Arm
Panitumumab
Cisplatin

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Induction CT+RT+PanitumumabExperimental Treatment4 Interventions
Panitumumab plus chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
Group II: Induction CT+RTActive Control3 Interventions
Chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
panitumumab
2010
Completed Phase 3
~1200
carboplatin
2010
Completed Phase 3
~4790
paclitaxel
1996
Completed Phase 3
~4310
surgery
2005
Completed Phase 4
~6010

Find a Location

Who is running the clinical trial?

Radiation Therapy Oncology GroupLead Sponsor
190 Previous Clinical Trials
64,856 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,932,252 Total Patients Enrolled
Martin J. Edelman, MDPrincipal InvestigatorUniversity of New Maryland
5 Previous Clinical Trials
897 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
2011. "Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00979212.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top